|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.
|
29990624 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Most guidelines for the management of patients with cardiovascular disease recommend angiotensin-converting enzyme (ACE) inhibitors as first-choice therapy, whereas angiotensin receptor blockers (ARBs) are merely considered an alternative for ACE inhibitor-intolerant patients.
|
29598869 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Captopril, an angiotensin-converting enzyme (ACE) inhibitor, has been widely used for therapy of arterial hypertension and cardiovascular diseases.
|
30183974 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors have been acknowledged as first-line agents for the treatment of hypertension and a variety of cardiovascular disorders.
|
30058413 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors (ACEI) are widely used in the management of cardiovascular diseases but with significant interindividual variability in the patient's response.
|
28587581 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The renin-angiotensin system blockers (RASBs), including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are widely used to reduce cardiovascular disease (CVD) events.
|
28387887 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The HD patients, particularly those with CVD, showed a significant increase in the levels of ACE and Ang II, whereas ACE2 and Ang-(1-7) levels were lower than those in the healthy controls.
|
29157100 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In the last 20 years, ACE-inhibitors (ACE-Is) have become the drugs of first choice for the treatments of the major CVDs.
|
28384411 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
During the last 25 years angiotensin-converting enzyme inhibitors spectacularly conquered the field of cardiovascular diseases therapy.
|
28636634 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
A1C = hemoglobin A1C ACE = angiotensin-converting enzyme ARB = angiotensin II receptor blocker CCB = calcium channel blocker CI = confidence interval CVD = cardiovascular disease DM = diabetes mellitus MI = myocardial infarction RR = relative risk.
|
27967225 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
ACEI = angiotensin-converting enzyme inhibitors; ADA = American Diabetes Association; ARB = angiotensin-receptor blocker; CAD = coronary artery disease; Cr = creatinine; CVD = cardiovascular disease; DM = diabetes mellitus; HF = heart failure; HT = hypertension; JNC = Joint National Committee; KAUH = King Abdullah University Hospital; LV = left ventricular; PAD = peripheral artery disease; RAAS = renin-angiotensin-aldosterone system; TIA = transient ischemic attack.
|
28816537 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cumulative relative risk of CVD events can be reduced by 75 % with a combination of aspirin, a β-adrenoceptor antagonist (β-blocker), an HMG-CoA reductase inhibitor (statin), and an angiotensin-converting enzyme inhibitor.
|
27778192 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Attainment of 5 secondary prevention parameters-aspirin use, lipid control (low-density lipoprotein cholesterol <70 mg/dL or statin therapy), blood pressure control (<140 mm Hg systolic, <90 mm Hg diastolic), angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, and nonsmoking status-was evaluated among 13 616 patients from 38 countries with diabetes mellitus and known cardiovascular disease at entry into TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
|
28626088 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Recent meta-analysis of large clinical trials on the use of ACE inhibitors and angiotensin receptor blockers in cardiovascular disease has demonstrated an imbalance between patients that significantly benefit from these therapeutic agents and those that remain at risk for heart disease progression.
|
28233239 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin I converting enzyme (ACE) insertion/deletion (I/D) polymorphism is thought to affect renin-angiotensin system (RAS) activity and development of cardiovascular disease; significant associations between I/D polymorphism and atherosclerosis, stroke, nephropathy, and early mortality were already found.
|
28190172 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The HF-diet-induced increase of ACE serum concentrations reveals ACE to be a potential molecular link between dietary fat intake and hypertension and cardiovascular disease (CVD).
|
28096099 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Results had shown the potential of S. siliquosum and S. polycystum in reducing cardiovascular diseases related risk factors following their inhibitory activities on ACE, α-amylase and α-glucosidase.
|
28847432 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Contradictory findings concerning the impact of the angiotensin-converting enzyme (ACE) gene on cardiovascular diseases have been reported.
|
28973758 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin system inhibition with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers has been shown to be effective in reducing progression of renal and cardiovascular disease.
|
28202167 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A total of nine gene variants/polymorphisms - F5 (Leiden - R5 06Q, rs6025), F2 (20210G > A, rs1799963), F13A1 (rs5985" genes_norm="2162">V34L, rs5985), MTHFR (677C > T - rs1801133;rs771406104;rs1455404812;s771406104" genes_norm="1636;2244;4524">A222V, rs1801133), MTHFR (1298A > C - rs1801131" genes_norm="4524">E429A, rs1801131), FGB (-455G > A -c.-463G > A; rs1800790), SERPINE1 (PAI14G/5G - rs1799889), ACE (ACE I/D, rs1799752), ITGB3 (GPIIIa L33P, rs5918) and the APOE E2/E3/E4 alleles (rs7412, rs429358) - were genotyped in 200 newly diagnosed ischemic stroke (IS) patients, 165 patients with ischemic coronary heart disease (CHD) and 159 controls with no cerebroor cardiovascular disease (non-CVD).
|
27629735 |
2016 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin-Converting Enzyme Insertion/Deletion polymorphism (ACE I/D polymorphism) has also be linked to cardiovascular diseases.
|
27022914 |
2016 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
ACE I/D polymorphism has been reported to be associated with various cardiovascular diseases.
|
26985916 |
2016 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
This might partly explain the reduced risk of developing diabetes and metabolic syndrome with RAS antagonists and offer insight into the origins of cardiovascular disease in which UCPs and ACE both play a role.
|
27417115 |
2016 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin-converting enzyme (ACE) gene I/D polymorphism is associated with many cardiovascular diseases.
|
26125265 |
2015 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The ACE I allele is found to be associated with T2DM; however, no association was observed with CVD.
|
26458572 |
2015 |